Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of upadacitinib in pediatric severe alopecia areata
jRCT2061260073Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in alopecia areata (5 arms), sponsored by AbbVie Inc. Primary endpoints: Achievement of SALT score <= 20 at week 24 and Adverse events. Started Oct 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on jRCT2061260073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260073.